Diazoxide Promotes Oligodendrocyte Precursor Cell Proliferation and Myelination

Birgit Fogal, Carolyn McClaskey, Sha Yan, Henglin Yan, Scott A. Rivkees*

Department of Pediatrics, Section of Developmental Biology and Endocrinology, Yale Child Health Research Center, Yale University School of Medicine, New Haven, Connecticut, United States of America

Abstract

Background: Several clinical conditions are associated with white matter injury, including periventricular white matter injury (PWMI), which is a form of brain injury sustained by preterm infants. It has been suggested that white matter injury in this condition is due to altered oligodendrocyte (OL) development or death, resulting in OL loss and hypomyelination. At present drugs are not available that stimulate OL proliferation and promote myelination. Evidence suggests that depolarizing stimuli reduces OL proliferation and differentiation, whereas agents that hyperpolarize OLs stimulate OL proliferation and differentiation. Considering that the drug diazoxide activates K<sub>ATP</sub> channels to hyperpolarize cells, we tested if this compound could influence OL proliferation and myelination.

Methodology/Findings: Studies were performed using rat oligodendrocyte precursor cell (OPC) cultures, cerebellar slice cultures, and an in vivo model of PWMI in which newborn mice were exposed to chronic sublethal hypoxia (10% O<sub>2</sub>). We found that K<sub>ATP</sub> channel components Kir 6.1 and 6.2 and SUR2 were expressed in oligodendrocytes. Additionally, diazoxide potently stimulated OPC proliferation, as did other K<sub>ATP</sub> activators. Diazoxide also stimulated myelination in cerebellar slice cultures. We also found that diazoxide prevented hypomyelination and ventriculomegaly following chronic sublethal hypoxia.

Conclusions: These results identify KATP channel components in OLs and show that diazoxide can promote OL proliferation in vitro. Importantly we find that diazoxide can promote myelination in vivo and prevent hypoxia-induced PWMI.

Introduction

In the United States, about 12% of infants are born prematurely [1], with very low birth weight (VLBW) (<1,500 gm) and extremely low birth weight (ELBW) (<1000 gm) infants accounting for about 20% of preterm births [1]. It is estimated that at least 25% of VLBW and ELBW infants will develop periventricular white matter injury (PWMI), which is one of the most common forms of brain injury affecting premature infants [2][3,4]. PWMI can include either diffuse white matter disease or focal necrosis, consisting of periventricular lesions [4,5,6]. Diffuse PWMI appears to be far more common than focal necrosis [2][3,4]. PWMI is associated with significant morbidity, as affected individuals may have profound intellectual impairment and cerebral palsy [5,7]. Highlighting the magnitude of PWMI, each year in the United States more than 400,000 infants are born prematurely [8]. Of these infants, about 100,000 are born at risk for PWMI, and about 25,000 children per year will develop PWMI. Finding a treatment for PWMI is thus of major clinical importance.

Oligodendrocytes (OLs) are the myelinating cells of the central nervous system [9,10]. OL development to mature myelin forming cells follows a complex series of events during which progenitor cells undergo dramatic morphological and biochemical changes [11]. Four stages of OL differentiation are distinguished: oligodendrocyte precursor cells (OPCs), late OL progenitors, immature OLs, and mature OLs [11]. It is believed that loss of the proliferative OPCs plays a major role in PWMI causation [5]. Recently, we observed that hypoxia induces premature maturation of OPCs, leading to decreases in numbers of replicating OPCs, resulting in fewer myelinating OLs in the brain [12]. As such, premature OPC maturation may contribute to hypomyelination in the developing brain [12]. At present, pharmacological approaches that promote OPC proliferation leading to enhanced brain myelination are not clinically available.

Available evidence shows that OLs express ion channels, [13,14,15,16] and changes in membrane potential and intracellular calcium levels influence OL development [17]. K channel blockers and depolarizing agents have been shown to cause G<sub>1</sub> arrest in the OPC cell cycle [18]. Agents that hyperpolarize OLs promote OL proliferation [14,15].

Compounds that influence K-channel activity are currently available for clinical use, and include diazoxide, which activates K<sub>ATP</sub> channels [19,20]. K<sub>ATP</sub> channels require two structurally
diverse subunits [19,20]. One subunit is a member of the pore-forming inward rectifier Kir6.x family of potassium channels, while the other subunit is a sulfonylurea receptor (SUR) [19,20], that belongs to the ATP-binding cassette superfamily.

We are unaware of studies that have examined the expression of Kir6 or SUR proteins in OLs. It is also not known if KATP channel antagonists or agonists effect OL development or function. We postulated that alteration in KATP channel activity could have potential utility as a therapeutic agent in white matter injury. To test this hypothesis we studied cultured OLs and validated models of PWMI [21].

Materials and Methods

Animals

This study was conducted in accordance with USDA guidelines for the use of experimental animals and was approved by the Institutional Animal Care and Use Committee (IACUC) of Yale University School of Medicine. CD1 and C57BL/6 mice and Sprague Dawley rats were obtained from Charles River Laboratories (Wilmington, MA). The Yale IACUC approval number for this study was #2008-11198. The Yale University Public Health Services approval number is A3230-01.

Cell culture

Purified OPC cultures were prepared as described [22,23]. In brief, primary rat mixed glial cell cultures were isolated from whole brains of postnatal day (P) 1 rats, dissociated into single cells, and cultured into poly-D-lysine (PDL, Sigma-Aldrich, St. Louis, MO) coated T75 tissue culture flasks. Plating medium consisted of Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS; InVitrogen, Carlsbad, CA), 2 mM L-glutamine, 100 mM streptomycin, and 10 μg/ml penicillin. Tissue cultures were maintained at 37°C in a humidified 5% CO2 incubator, and medium was exchanged every 3 days. Once confluent (after 7–9 days), microglia were separated by mechanical shaking of flasks on a rotary shaker for 60 min at 200 rpm and removed. After addition of fresh medium, the remaining cells were allowed to recover overnight before repeating the mechanical shaking for an additional 16 h at 200 rpm to isolate OPCs. To ensure purity of OPC cultures, the isolated cells were transferred to a tissue culture dish, from which the loosely attached OPCs were detached by gentle shaking after 60 min, leaving behind attached microglia and astrocytes. OPCs were plated onto PDL coated 96 well plates using an automated dispenser and allowed to adhere to the plates over the next 1–2 days. In agreement with others [24], this procedure yields 90% A2B5-positive (OPC marker), and 2% MBP-positive (mature OL marker) cells. GFAP-positive (astrocyte marker) or O2A-positive (microglia marker) cells cannot be detected in cultures prepared in this manner.

Drug exposure

Cells were exposed to KATP channel stimulators for 72–96 h. The compounds included commercially available KATP channel activators ZM26600 (2.5 μM), Pinacidil (10 μM), Y26763 (200 nM), Levcromakalim (2.5 μM), P1075 (100 nM) and diazoxide. Cultures were washed twice with DMEM to remove any residual serum and then the respective solutions of KATP channel activators were added daily in an incubation buffer of DMEM with 0.3% FBS +10 μg/ml biotin and N2 supplement. Cells were then placed at 37°C in a humidified atmosphere containing 5% CO2.

Quantification of cell number

To evaluate cell proliferation in response to KATP channel stimulators, we utilized the CyQUANT® NF Cell Proliferation assay (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. This assay measures cellular DNA content as a direct index of cell proliferation. Since cellular DNA content is highly proportional to cell number, this is a very accurate way to assess cell proliferation specifically [25]. At the end of drug exposure, medium was removed and a stock solution of the green-fluorescent CyQUANT GR dye (prepared according to manufacturer’s instructions) was added. Upon binding to DNA, the GR dye shows a measurable enhancement in fluorescent intensity. Cells were returned to the incubator (37°C) for 2 h, which we determined to result in maximal and stable changes in fluorescence. Fluorescence was measured using an Envision Multilabel reader (Perkin-Elmer; Excitation: 480 nm, Emission: 530 nm).

Calcium imaging

Calcium imaging was performed by using an Olympus Fluoview confocal laser scanning microscope (IX70, Melville, NY), an UPlanFl 20x objective (NA.0.5), and Fluoview image processing software (v2.1). To assess intracellular calcium levels the calcium ionophore Fluo-3 was used.

Cells were first evaluated before the addition of any drug. After addition of drug, calcium levels were recorded. Quantification and statistical analysis of quantified data was performed by using Fluoview software, Microsoft Excel 2000 (Microsoft, Inc., Redmond, WA), and GraphPad Prism (v3.0, GraphPad Software, Inc., San Diego, CA), as described [26].

Cerebellar Slice Cultures

Cerebellar organotypic cultures of mice (postnatal 0 day) were prepared as described [27,28]. 300-μm thick slices were transferred onto membranes of 30 mm Millipore culture inserts with a 0.4 μm pore size, and maintained in six-well tissue culture plates containing 1 ml of medium at 35°C in room air with 5% CO2. The nutrient medium consisted of 50% basal medium with Earle’s salts, 25% horse serum, 25% Hank’s balance solution, 1 mM L-glutamine, and 5 mg/ml glucose. After 24 h the medium was removed and culture plates were washed twice with phosphate-buffered saline before addition of tolbutamide, diazoxide, or vehicle in N1 medium. After five days cultures were immunostained for MBP as described below. Total numbers of MBP-positive cells and myelinated fibers per mm2 area were determined for each slice by manual counting by an individual who was blinded to treatment conditions. Each treatment condition contained six slices from three different animals.

Polymerase chain reaction

cDNA was made from OPCs and mature OLs. DNA was amplified from cells and used in PCR reactions with SUR or Kir6 subtype-specific primers, as detailed [29].

Western blot analysis

Cells were washed in ice-cold phosphate buffered saline (PBS) and lysed using hot lysis buffer containing 42 mM Tris-HCl (pH 6.8), 1.3% sodium dodecyl sulfate (SDS), 6.5% glycerol, and 0.1 mM sodium orthovanadate. Protein concentrations were determined using the bicinechonic acid method (BCA kit, Pierce). The following primary antibodies were used: anti-β-actin (1:5000; Sigma), anti-β3 (1:5000; Santa Cruz, Santa Cruz, CA), anti-kir6.1 (1:5000; Santa Cruz), anti-kir6.2 (1:5000; Santa Cruz), anti-kir6.3 (1:5000; Santa Cruz), anti-sur1 (1:5000; Santa Cruz), anti-sur2a (1:5000; Santa Cruz), and anti-sur2b (1:5000; Santa Cruz). Blots were developed using an enhanced chemiluminescence detection kit (ECL; Amersham). The Odyssey infrared imaging system (Li-Cor Bioluminescence Imaging System) was used to monitor and analyze the fluorescent responses.
membrane, and blocked with 5% non-fat dry milk in 20 mM Tris-HCl, pH 7.6, 150 mM sodium chloride and 0.1% tween-20 (TBS-T) for 1 hr. Anti Kir6.1 and 6.2 and SUR1 and 2a antibodies were obtained from Santa Cruz Biotechnology (Carlsbad, CA). Secondary antibodies were diluted in blocking buffer and incubated for 1 hr at RT. Horseradish peroxidase-conjugated goat anti-rabbit antibody (1:5000 dilution) was used to detect labeled product. After washing, proteins were detected using an enhanced chemiluminescence kit (Pierce Biotech).

In vivo Hypoxia

C57BL/6 mice were exposed to low or normal oxygen conditions from P3-P12 as described [21,30]. In brief, litters of pups (P3) were placed with the dam in a Plexiglas chamber, in which oxygen levels were maintained at 9.5 ± 1.0%. O2 levels were continuously monitored using a Cameron Instrument (Ontario, Canada) dual channel oxygen monitor attached to O2 electrodes placed at each end of the chamber. Control animals were kept in room air (~22%) outside the Plexiglas chamber. Because C57BL/6 dams do not normally care for pups in hypoxic conditions, pups (hypoxia and control) were cross-fostered with CD1 dams, which were placed in the same cage before birth of pups. Animals were removed from the chamber daily for less than 15 min to allow for diazoxide (10 mg/kg i.p.) or vehicle administration, as well as observation of weight gain. Mice were euthanized at P12, brains were harvested and shock frozen in ice cold (~20°C) 2-methylbutane and stored at −80°C until assessment of ventricular size or MBP immunocytochemistry (see below). At least eight animals were studied in each treatment group. There were no difference in mortality observed between the vehicle and diazoxide treated pups. Mortality rates were less than 12% for each treatment group (p > 0.05).

Quantification of ventricular size

Ventricle size was determined as reported [30,31]. Animals were weighed, anesthetized, and decapitated. Brains were shock frozen in ice cold (~20°C) 2-methylbutane and stored at −80°C until assessment of ventricular size or MBP immunocytochemistry (see below). At least eight animals were studied in each treatment group. There were no difference in mortality observed between the vehicle and diazoxide treated pups. Mortality rates were less than 12% for each treatment group (p > 0.05).

Immunostaining

Tissue sections were fixed with 4% paraformaldehyde in PBS for 30 min at room temperature and incubated with 10% normal goat serum plus 0.3% Triton X-100 in 0.1 M PBS (pH 7.4) overnight to block nonspecific binding. The sections were incubated with monoclonal MBP antibody (SMI-99, Covance, Princeton, NJ) at a dilution of 1:1000 in PBS with 10% normal goat serum plus 0.1% Triton X-100 at 4°C overnight, followed by incubation of Alexa Fluor 495 anti-mouse IgG (Molecular Probes) at a dilution of 1:400. The intensity of labeling was assessed using Image J Version 1.42q (National Institutes of Health, Bethesda MD) at the mid-level of the corpus callosum from three slides per animal.

For A2B5 and O1, immunocytochemistry was performed as described [32]. Cultures were washed twice with L-15 medium. Cells were then incubated with murine monoclonal antibodies, or A2B5, O1 hybridoma culture supernatants for 20 min at 37°C. Cells were incubated with Alexa Fluor 594- or Alexa Fluor 488-conjugated antimouse secondary antibody (1:200) for 20 min at 37°C.

For Kir and SUR immunostaining, cells were fixed with 4% paraformaldehyde and treated with 0.2% Triton X-100 and 10% goat serum. Next, cells were incubated with monoclonal anti-Kir6.1 and 6.2 and SUR1 and 2a (Santa Cruz Biotechnology; Carlsbad, CA; 1:100-500) or mouse IgG (control) plus 10% normal goat serum overnight at 4°C. After washing three times with PBS, cells were incubated with goat anti-mouse IgG conjugated to Alexa Fluor 594, or goat anti-rabbit IgG conjugated to Alexa Fluor 488 for 90 min at room temperature. Cells were examined by fluorescence microscopy.

Statistical Analysis

All experiments were performed at least three times and statistical analyses were performed using Graph Pad Prism software. Comparisons among multiple groups were made by ANOVA, with Bonferroni post-test comparisons. Paired comparisons were made by the Students-T test. In all experiments significance was assessed at p < 0.05.

Results

Expression of SUR and Kir6 in OLs

We postulated that OLs contain KATP channels that could be pharmacological targets. To begin to address this issue, we examined the expression KATP channel components SUR and Kir6.1 and 6.2 in OLs. First, we assessed Kir6.1 and 6.2 and SUR gene expression in OLs by PCR. cDNA was made from OPCs and mature OLs. For OPC studies, 98% of cells were A2B5-positive; for mature OL studies, 95% of cells were MBP-positive.

DNA was amplified from cells and used in PCR reactions with SUR or Kir6 subtype-specific primers, as reported [29]. Kir6.1 and Kir6.2, as well as SUR1 and SUR2 mRNA expression was observed in both, OPCs (Fig. 1) and mature OLs (data not shown). Next, we examined SUR and Kir protein expression using immunoblotting. We observed bands of the appropriate sizes for Kir6.1 (51 kDa), Kir6.2 (40 kDa), SUR1 (150 kDa), and SUR2 (180 kDa) in protein lysates prepared from whole brain. Using lysates from OPCs, Kir 6.1, Kir 6.2, and SUR2, but not SUR1 protein expression was detected (Figure 2). These results were confirmed by immunocytochemistry, in which Kir6.1, Kir 6.2, and SUR2 positive cells were detected in both OPC (A2B5 positive) and mature OL (O1 positive) cultures, whereas, SUR1 labeling was not present (Figure 3). These data show that OPCs express SUR2 and Kir6.1 and 6.2 genes and proteins, which are components of KATP channels.

Figure 1. PreOLs express Kir6.1, Kir6.2, SUR1 and SUR2 genes. cDNA was prepared from OPCs and used in PCR reactions with primers specific to each gene. 98% of cells were A2B5-positive indicating that cells were OPCs. Left, molecular weight markers. White bands show amplified products. Data shown are representative of three separate studies performed on OPC cultures prepared at different times. Similar observations (not shown) were seen for mature OLs (95% MBP-positive).

doi:10.1371/journal.pone.0010906.g001
Influences of KATP activation on OPC proliferation

We next assessed the potential of KATP activation to stimulate OPC proliferation using the KATP channel activator diazoxide [33]. Cultured OPCs were treated with concentrations of diazoxide ranging from 0.1 to 100 μM for 72–96 h. To evaluate cell proliferation in response to KATP channel stimulators, we utilized the CyQUANT® NF Cell Proliferation assay (Invitrogen, Carlsbad, CA) which is a validated method for assessing cell proliferation [25]. This assay measures cellular DNA content as a direct index of cell proliferation. Since cellular DNA content is highly proportional to cell number, this is a very accurate way to assess cell proliferation specifically [25].

Diazoxide stimulated OPC proliferation in a dose-dependent manner (Fig. 4). Interestingly, a typical concentration-response curve was not observed suggesting that a threshold level of drug may need to be achieved to trigger a response. We also tested the effect of other commercially available KATP channel activators on OPC proliferation. Namely, ZM26600 (2.5 μM), Pinacidil (10 μM), Y26763 (200 nM), Levromakalim (2.5 μM), P1075 (100 nM) were tested using fixed doses, based on known effective concentrations [34]. As with diazoxide, OPC proliferation was increased by these known KATP channel activators, with several compounds being more potent than diazoxide (Fig. 5).

Influences on intracellular calcium levels

We next examined if KATP activators and blockers influence intracellular calcium levels [35], as changes in KATP activity influence intracellular calcium levels and cell proliferation [35]. After OPCs were loaded with the calcium ionophore Fluo3/AM, they were treated with diazoxide (10 μM) while being visualized by confocal imaging. We also tested the KATP channel blocker tolbutamide (100 μM). Tolbutamide blocks KATP channels, thus we tested if this compound influence intracellular calcium levels in a way opposite that observed for diazoxide which activates KATP channels.

We observed that intracellular calcium levels decreased when cells were treated with diazoxide. In contrast, addition of tolbutamide to the medium induced prompt intracellular calcium increases (Fig. 6).

Influences on myelination in vitro

After the above studies, we assessed if KATP channel activation or blockade influences myelination using cerebellum slice cultures. In cerebellar brain slices, microglia, OLs and neurons are present [28]. In addition, axon growth and myelination occurs in slices, providing an excellent model for examining influences on myelination and axon growth [36].

Slices were prepared from P0 mice. After 2 days in culture, slices were treated with diazoxide (10 μM) or tolbutamide (100 μM) for 5 days, followed by immunostaining for MBP. As above, because tolbutamide blocks KATP channel activation, we tested if this compound influence slice culture myelination in a way opposite that observed for diazoxide.

In the diazoxide-treated slices, we observed large numbers of myelinated fibers (38±4 MBP-positive fibers/slice) that exceeded numbers observed with vehicle treatment (23±3 MBP-positive fibers/slice) (Fig. 7). In tolbutamide-treated specimens, myelinated fibers were sparse (9.6±3 MBP-positive fibers/slice) and less than that observed in vehicle-treated slices.

Protective effects of diazoxide on hypoxia-induced PWMI

Considering the effects of diazoxide treatment on OPCs and myelination observed in vitro, we assessed if diazoxide could confer protection against hypoxia-induced PWMI using the chronic sublethal hypoxia model [21,30]. Whereas different models have been used to recapitulate human infant white matter injury [37], no model exactly recapitulate the human lesion. However, the chronic sublethal hypoxia model mirrors the diffuse PWMI phenotype [21], which is the most common form of white matter injury in premature infants.

C57BL/6 mice were reared in room air or 10% O2 from P3 to P12, and treated daily with diazoxide (10 mg/kg i.p.) or vehicle.
The dose of 10 mg/kg was used as this is typically used in clinical settings [38]. We observed that mice reared under hypoxic conditions gained less weight than mice reared in normoxia. Weight gain overtime was similar in mice treated with vehicle or diazoxide under normal oxygen conditions. However, diazoxide-treated animals show a trend for better weight gain under hypoxic conditions, although this difference was not significant.

Figure 4. Concentration-response effects of diazoxide on PreOL proliferation. Data shown are from three studies in which each concentration was tested in triplicate in each study. * p<0.05, vs. vehicle, ANOVA. Mean ± SEM shown. Y-axis represents the percent increase relative to control in cellular DNA content, which is a direct index of cell proliferation.

doi:10.1371/journal.pone.0010906.g004

Diazoxide and Myelination

When ventricle size was assessed (Fig. 8), we observed ventriculomegaly in the hypoxia-vehicle group (2.86×10^6 ± 0.3×10^6). In the hypoxia-diazoxide group, the ventricles were not enlarged (1.37×10^6 ± 0.2×10^6) (p<0.05; ANOVA). In normoxic conditions ventricle sizes were similar in pups treated with vehicle (1.93×10^6 ± 0.6×10^6) or diazoxide (1.38×10^6 ± 0.4×10^6) (p>0.05; ANOVA).

Additionally, myelination was assessed via immunostaining for MBP. Compared to animals reared under normal oxygen conditions, animals kept under hypoxia showed a reduction in MBP labeling. Importantly, in diazoxide-treated mice reared under hypoxia, MBP labeling appeared similar to control animals. (p<0.01, ANOVA; Figs. 9 and 10). Interestingly, diazoxide treatment in animals reared under normoxic conditions manifested slight, but significant increases in MBP staining (p<0.01, ANOVA; Figs. 9 and 10).

Discussion

The above data identify diazoxide as a potent stimulator of OPC proliferation and myelination. We observe that OPCs express K_ATP channels and that diazoxide and other K_ATP channel activators stimulate OPC proliferation. We also show that diazoxide can prevent hypoxia-induced ventriculomegaly and hypomyelination, which are features of PWMI.

Available evidence suggests that it is possible to alter OPC proliferation and differentiation with exogenous compounds including platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) [39]. None of these compounds, though, are available for clinical use, and their potential therapeutic utility is limited by their peptide nature [39].

We find that diazoxide, which activates K_ATP channels [33], stimulates OL proliferation and promotes myelination during...
early development. Diazoxide acts on inwardly rectifying KATP channels that close when ATP levels are high [33,35]. Other KATP channel activators include ZM26600, pinacidil, Y26763, levcromakalim, and P1075 [33]. We observed that the other KATP channel activators tested stimulated OPC proliferation, as well.

KATP channels are unique among Kir channels in that they require two structurally diverse subunits in a stoichiometry of 4:4 to form functional channels [20]. One subunit is a member of the inward rectifier Kir6.0 family of potassium channels; the other subunit is a sulfonylurea receptor (SUR) [19,20]. The subunit composition of KATP channels varies among different tissues, with different SUR subtypes interacting with Kir6.1 or Kir6.2 [19,20]. Kir6.2/SUR1 is found in pancreatic cells; Kir6.2/SUR2A is found in cardiac KATP. Kir6.1/SUR1 is found in mitochondrial channels [40,41]. We observed that OL expressed both Kir6.1 and Kir6.2 and SUR2. Although we observed SUR1 gene expression by PCR, we did not detect protein expression either by immunoblotting or immunocytochemistry.

Interestingly, the sensitivity of KATP channels to the different KATP channel activators depends in large part on their subunit composition.

Figure 6. Diazoxide inhibits intracellular calcium accumulation. Data points are the mean ± SEM of 30 separate cells. 100 depicts baseline Fluo-3 intensity. Drugs administered at 0 seconds. These data are representative of 3 separate studies. Tolbutamide (100 uM), diazoxide (10 uM). doi:10.1371/journal.pone.0010906.g006

Figure 7. Diazoxide stimulates myelinated fiber formation. Slice cultures from P0 cerebellum were treated with diazoxide (1 uM), tolbutamide (100 uM), or vehicle for 5 days. Slices were stained for MBP. A. Top panel shows quantitative assessment of myelinated fiber number (p<0.01; ANOVA). Data are mean ± SEM from six separate slices per treatment. B. Images of MBP labeled specimens. doi:10.1371/journal.pone.0010906.g007
composition [34]. For example, pancreatic K\(_{\text{ATP}}\) channels composed of SUR1/Kir6.2 subunits are highly sensitive to diazoxide, but less sensitive to pinacidil and levcromakalim, while cardiac K\(_{\text{ATP}}\) channels (SUR2A/Kir6.2) are activate by cromakalim and pinacidil but not diazoxide [34]. However, diazoxide can also activate Kir6.1 alone [42]. Although beyond the scope of this study to determine the exact composition and stoichiometry of OL K\(_{\text{ATP}}\) channels, the observed effects of the different K\(_{\text{ATP}}\) channel activators on OPC proliferation supports the presence of SUR2A/B and Kir6.1/Kir6.2, subunits in OPCs.

Available evidence shows that OLs express ion channels [14,15,16]. Although not extensively studied, changes in membrane potential and intracellular calcium levels have been observed to influence OL development [17]. In rats, OLs express an inwardly rectifying K-current (IKIR), which are G protein-regulated [43]. Kir4.1 expression has been detected in OLs [44]. Showing that altered channel activity alters OL development, blockade of K channels in OPCs inhibits cell proliferation [45,46]. Studies of Kir4.1 knockout mice reveal undermyelination of the brain [14], suggesting that the Kir4.1 channel subunit is crucial for OL maturation.

K channel blockers and depolarizing agents cause G1 arrest in the OPC cell cycle. There is also accumulation of p27\(^{kip1}\) and p21\(^{cip1}\) in OLs, which regulate cell proliferation and differentiation [47,48,49,50]. Elevated p27 is associated with premature exit from the cell cycle and cessation of proliferation [47,48,49,50].

Figure 8. Animals reared in chronic hypoxia and treated with diazoxide demonstrate reductions in ventriculomegaly. A. Top panel shows quantitative assessment of ventricle size. Data shown are mean ± SEM from one experiment with 4–6 animals per treatment group (p < 0.01; t-test). Similar results were obtained in another separate study performed at a different time. Chronic hypoxia caused pronounced ventriculomegaly (arrow). Note the reduction in ventricle size in the mice treated with diazoxide. B. Photographs are from one animal in each treatment group. * p < 0.01 ANOVA.

doi:10.1371/journal.pone.0010906.g008

These effects on cell proliferation appear to involve changes in intracellular calcium levels [17,51,52]. When intracellular calcium levels rise, proliferation is reduced in favor of maturation [51,52].

Figure 9. Animals reared in chronic hypoxia and room air demonstrate increased myelination with diazoxide treatment. Coronal images at level of corpus callosum shown are from one experiment with 4–6 animals per treatment group and are representative of one other separate study performed at a different time. MBP staining was performed at the same time. Box depict region of corpus callosum where labeling intensity was assessed. Photographs were taken at identical exposures. Hypoxia caused diffuse reduction in cerebral MBP-labeling, which was markedly improved with diazoxide. We also observed more MBP-labeling in diazoxide-treatment mice reared in room air compared to those treated with vehicle.

doi:10.1371/journal.pone.0010906.g009

Figure 10. Animals reared in chronic hypoxia and room air demonstrate increased myelination with diazoxide treatment. Quantitative assessment of labeling using Image J Version 1.42q (National Institutes of Health, Bethesda MD) at the mid-level of the corpus callosum of groups shown in Fig. 9. Data shown are mean ± SEM from one experiment with 3–6 animals per treatment group. Similar results were obtained in another separate study performed at a different time.

doi:10.1371/journal.pone.0010906.g010
When intracellular calcium levels fall, proliferation is increased and cells do not mature [51,52]. Consistent with this notion, we find that diazoxide results in decreases in intracellular calcium levels, whereas tolbutamide triggers increases in intracellular calcium levels. It is important to highlight that we only examined acute changes in intracellular calcium levels in response to treatment with diazoxide and tolbutamide. Future studies are indicated to discern the duration of such responses and whether chronic exposure to if K<sub>ATP</sub> channel agonists and antagonist influences changes in cell membrane potential and intracellular calcium levels.

When we examined myelination in slice culture models, we observed that diazoxide stimulated myelination and tolbutamide inhibited myelination. Interestingly, in newborn mice treated with diazoxide in room air, we observed that diazoxide stimulated myelination, above that observed in control animals. Further studies are thus indicated to assess if K<sub>ATP</sub> Channel agonists could result in hypermyelination or abnormal dysmyelination.

It is also important to note that the cerebellar slice culture model and the in vivo studies of developing pups provided complementary models for assessing effects of diazoxide on myelination. In both models, we observed that there was more myelination in the diazoxide-treated groups than those treated with vehicle. The presence of increased myelination in the two different model systems supports the notion that diazoxide can indeed promote myelination in different brain regions.

We recognize that no in vivo model completely recapitulates human white matter injury. Thus in future studies it will be interesting to examine effects in other models of white matter injury, such as those caused by hypoxic-ischemic or inflammatory insults. Whereas it is likely that the favorable effects of diazoxide on myelination in the models used represent are direct effects on OLs, additional studies are indicated to determine if this is a direct effect of diazoxide or an indirect effect mediated by other brain cell types. Studies of ultrastructural analysis will also be revealing in assess axon myelination.

Previously, we reported that caffeine confers protective effects against hypoxia-induced white matter injury in development [31]. In comparison with those observations, in the identical model, we find diazoxide to be more effective in promoting myelination. We also recently performed high-throughput screening of chemical libraries using the GenPlus Custom Collection (MicroSource Discovery Systems, Inc; Gaylordville, CT) and a library from Maybridge (Cornwall, UK). Of 14,700 compounds screened, none were as potent as diazoxide in stimulating OPC proliferation under the same experimental conditions (SAR and BF, unpublished observations).

Currently, diazoxide is FDA approved for the treatment of hyperinsulinism in infants [53]. Diazoxide has been used in infants for extended periods with a favorable safety profile [54]. Considering that no FDA approved drugs are currently available for the treatment of PWMI or other hypo- or demyelinating conditions, further studies are indicated to assess the utility of diazoxide as a potential therapeutic. It is also possible that other K<sub>ATP</sub> channel activators that specifically target OL K<sub>ATP</sub> channel components may prove to be even more effective.

**Acknowledgments**

Ryan Poulsen and Sarah Rhenzi are thanked for technical assistance.

**Author Contributions**

Conceived and designed the experiments: BF HY SAR. Performed the experiments: BF CM HY SAR. Analyzed the data: BF CM HY SAR. Wrote the paper: BF SAR.

**References**

1. Muglia LJ, Katz M (2010) The Enigma of Spontaneous Preterm Birth. N Engl J Med 362: 529–535.

2. Bodensteiner JB, Johansen SD (2006) Magnetic resonance imaging (MRI) findings in children surviving extremely premature delivery and extremely low birthweight with cerebral palsy. J Child Neurol 21: 743–747.

3. Wilson-Costello D, Friedman H, Minich N, Fanaroff AA, Hack M (2003). Improved survival rates with increased neurodevelopmental disability for extremely low birth weight infants in the 1990s. Pediatrics 115: 997–1003.

4. Volpe JJ (2001) Neurobiology of periventricular leukomalacia in the premature infant. Pediatr Res 50: 553–562.

5. Back SA (2006) Perinatal white matter injury: the changing spectrum of pathology and emerging insights into pathogenetic mechanisms. Ment Retard Dev Disabil Res Rev 12: 129–140.

6. Kinney HC, Back SA (1998) Human oligodendroglial development: relationship to periventricular leukomalacia. Semin Pediatr Neurol 5: 180–189.

7. Volpe JJ (2009) Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurol 8: 110–124.

8. Rushing S, Ment LR (2004) Preterm birth: a cost benefit analysis. Semin Pediatr Neurol 5: 180–189.

9. Kinney HC (2005) Human myelination and perinatal white matter disorders. J Neurosci 25: 196–192.

10. McLauren JA, Yong VW (1995) Oligodendrocytes and myelin. Neuron 13: 23–49.

11. Craig A, Luo NL, Beardsley DJ, Wingate-Pearse N, Walker DW, et al. (2003) Quantitative analysis of rodent oligodendrocyte lineage progression and its correlation with human. Exp Neurol 181.

12. Kim HC, Fujimoto Y, Saito K, Takeuchi Y, Kato S, et al. (2003) High myelination in the mature rat optic nerve. Exp Neurol 202: 36–43.

13. Gipson K, Bordey A (2002) Analysis of the K<sub>ATP</sub> potasium channel subunit is crucial for oligodendrocyte development and in vitro myelination. J Neurosci 21: 5429–5439.

14. Williamson AV, Compton DA, Randall AD (1997) Analysis of the ion channel complement of the rat oligodendrocyte progenitor in a commonly studied in vitro preparation. Eur J Neurosci 9: 706–720.

15. Barres BA, Koroshetz WJ, Swartz KJ, Chan LL, Corey DP (1990) Ion channel expression by white matter glia: the O-2A glial progenitor cell. Neurogn 4: 507–524.

16. Knutsen P, Ghiani CA, Zhou JM, Gallo V, McBain CJ (1997) K<sup>+</sup> channel expression and cell proliferation. are regulated by intracellular potassium and membrane depolarization in oligodendrocyte progenitor cells. J Neurosci 17: 2609–2620.

17. Bolton S, Butt AM (2006) Cyclic AMP-mediated regulation of the resting membrane potential in myelin-forming oligodendrocytes in the isolated intact rat optic nerve. Exp Neurol 202: 36–43.

18. Babenko AP, Gonzalez G, Bryan J (2000) Pharmacological properties of type V1A receptors. Separate domains of the regulatory subunits of K<sub>ATP</sub> channel isoforms are required for selective interaction with K<sup>+</sup> channel openers. J Biol Chem 275: 717–720.

19. Babenko AP, Aguilar-Bryan L, Bryan J (1998) A view of sur/K<sub>IR6.6</sub>, K<sub>ATP</sub> channels. Annu Rev Physiol 60: 667–687.

20. Ment LR, Schwartz M, Makisch RW, Stewert WB (1998) Association of chronic sublethal hypoxia with ventriculomegaly in the developing rat brain. Brain ResearchDevelopmental Brain Research 111: 197–203.

21. McCarthy KD, de Vellis J (1980) Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85: 900–920.

22. Othman T, Yan H, Rieszka SA (2003) Oligodendrocytes express functional A1 adenosine receptors that stimulate cellular migration. Glia 44: 166–172.

23. Niu W, Yu Y, DiAugustine RP, Richards RG, D’Ercole AJ (2002) Myelination is altered in insulin-like growth factor-I null mutant mice. J Neurosci 22: 16269–2682.

24. Ding Y, Fan S, Charron M, Grady J, Barres BA (2006) Functional genomic analysis of oligodendrocyte differentiation. J Neurosci 26: 10967–10983.

25. Jones LJ, Gray M, Yue ST, Haugland RP, Singer VL (2001) Sensitive determination of cell number using the CyQUANT cell proliferation assay. J Immunol Methods 245: 85–98.

26. Porter GA, Jr., Makuck RF, Rivkees SA (2002) Reduction in intracellular calcium levels inhibits myoblast differentiation. J Biol Chem 277: 28942–28947.

27. Yan H, Rieszka SA (2006) Hypoglycemia influences oligodendrocyte development and myelin formation. Neuronrport 17: 55–59.

28. Martin-Teva JL, Duart I, Colin C, Gervais A, van Rooijen N, et al. (2004) Microglia promote the death of developing Parkin gene. J Biol Chem 279: 535–547.

29. Ye P, Li L, Richards RG, DiAugustine RP, D’Ecole Aj (2002) Myelination is altered in insulin-like growth factor-I null mutant mice. J Neurosci 22: 6614–6615.
30. Turner CP, Schi M, Ment L, Stewart W, Yan H, et al. (2003) A1 adenosine receptors mediate hypoxia-induced ventriculomegaly. Proc Natl Acad Sci U S A 100: 11718–11722.

31. Back SA, Craig A, Luo NL, Ren J, Akundi RS, et al. (2006) Protective effects of caffeine on chronic hypoxia-induced perinatal white matter injury. Ann Neurol 60: 696–705.

32. Yan H, Rivkees SA (2002) Hepatocyte growth factor stimulates the proliferation and migration of oligodendrocyte precursor cells. J Neurosci Res 69: 397–406.

33. Arval KS (1994) Pharmacology and structure-activity relationships for KATP modulators: tissue-selective KATP openers. J Cardiovasc Pharmacol 24 Suppl 1: S12–17.

34. Gribble FM, Reimann F (2002) Pharmacological modulation of K(ATP) channels. Biochem Soc Trans 30: 333–339.

35. Adebiyi A, McNally EM, Jaggar JH (2008) Sulfonylurea receptor-dependent and -independent pathways mediate vasodilation induced by ATP-sensitive K+ channel openers. Mol Pharmacol 74: 736–743.

36. Bouslama-Oueghlani L, Wehrle R, Sotelo C, Dusart I (2003) The developmental loss of the ability of Purkinje cells to regenerate their axons occurs in the absence of myelin: an in vitro model to prevent myelination. J Neurosci 23: 8318–8329.

37. Rice JE, III, Vannucci RC, Brierley JB (1981) The influence of immaturity on hypoxic-ischemic brain damage in the rat. Annals of Neurology 9: 131–141.

38. Pinney SE, MacMullen C, Becker S, Lin YW, Hanna C, et al. (2006) Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations. J Clin Invest 118: 2877–2886.

39. McKinnon RD, Matsui T, Dubois-Dalcq M, Aaronson SA (1990) FGF modulates the PDGF-driven pathway of oligodendrocyte development. Neuron 5: 603–614.

40. Tai KK, McCrossan ZA, Abbott GW (2003) Activation of mitochondrial ATP-sensitive potassium channels increases cell viability against rotenone-induced cell death. J Neurochem 84: 1195–1200.

41. Liu Y, Ren G, O’Rourke B, Marban E, Scharayon J (2001) Pharmacological comparison of native mitochondrial K(ATP) channels with molecularly defined surface K(ATP) channels. Mol Pharmacol 59: 225–230.

42. Groenendaal F, van der Grond J, Eken P, van Haastert IC, Rademaker KJ, et al. (1997) Early cerebral proton MRS and neurodevelopmental outcome in infants with cystic leukomalacia. Dev Med Child Neurol 39: 373–379.

43. Karschin A, Wcichmeyer E (1995) Identification of G protein-regulated inwardly rectifying K+ channels in rat brain oligodendrocytes. Neurosci Lett 180: 135–138.

44. Kalsi AS, Greenwood K, Wilkin G, Butt AM (2004) Kir4.1 expression by astrocytes and oligodendrocytes in CNS white matter: a developmental study in the rat optic nerve. J Anat 204: 473–485.

45. Pappas CA, Ulrich N, Sontheimer H (1994) Reduction of glial proliferation by K+ channel blockers is mediated by changes in pH. Neuropeptide 6: 193–196.

46. Gallo V, Zhou JM, McBain CJ, Wright P, Knutson PL, et al. (1996) Oligodendrocyte progenitor cell proliferation and lineage progression are regulated by glutamate receptor-mediated K+ channel block. J Neurosci 16: 2659–2670.

47. Pagano M (2004) Control of DNA synthesis and mitosis by the Skp2-p27-Cdk1/2 axis. Mol Cell 14: 414–416.

48. Blain SW, Scher HI, Gordon-Cardo C, Koff A (2003) p27 as a target for cancer therapeutics. Cancer Cell 3: 111–115.

49. Coqueret O (2003) New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 13: 65–70.

50. Mayam SI, Nguyen D, Zohel F, Piz C, Heise S, et al. (2006) Modulation of rat oligodendrocyte precursor cells by the chemokine CXCL12. Neuron 50: 1107–1110.

51. Maysami S, Nguyen D, Zohel F, Piz C, Heise S, et al. (2006) Modulation of rat oligodendrocyte precursor cells by the chemokine CXCL12. Neuron 50: 1107–1110.

52. Simpson PB, Russell JT (1998) Mitochondrial Ca2+ uptake and release influence metabolic and ionotropic cytosolic Ca2+ responses in rat oligodendrocyte progenitors. J Physiol 508 (Pt 2): 413–426.

53. US Food and Drug Administration Webite. Diazoxide. (2010) Available: http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fa=saction=&Search. Overview&DrugName=DIAZOXIDE. Accessed 2010 May 12.

54. Stanley CA (2006) Hypoglycemia in the neonate. Pediatr Endocrinol Rev 4 Suppl 1: 76–81.